Soligenix Inc. Cash Flow Conversion Efficiency
Soligenix Inc. cash flow conversion efficiency. Based on the latest financial reports, Soligenix Inc. (SNGX) has a cash flow conversion efficiency ratio of -0.257x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.71 Million) by net assets ($6.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Soligenix Inc. (1995–2025)
Cash flow conversion efficiency of Soligenix Inc. from 1995 to 2025. This chart illustrates how Soligenix Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View SNGX share price today for real-time trading data and today's change.
Soligenix Inc. Cash Flow Conversion Ratio Explained
Soligenix Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Soligenix Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Soligenix Inc. ranked by their cash flow conversion efficiency. Also see how much is Soligenix Inc. worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bima Sakti Pertiwi Tbk PT
JK:PAMG
|
0.004x |
|
SG COMPANY S.P.A.
F:7KZ
|
N/A |
|
Korea Plasma Technology U Co.Ltd
KQ:054410
|
0.004x |
|
Pudjiadi Prestige Tbk
JK:PUDP
|
-0.009x |
|
Techstep ASA
OL:TECH
|
0.098x |
|
Emerson Radio Corporation
NYSE MKT:MSN
|
-0.106x |
|
SunLink Health Systems Inc
NYSE MKT:SSY
|
-0.190x |
|
IMAGIS Co. Ltd
KQ:115610
|
-0.217x |
Annual Cash Flow Conversion Efficiency for Soligenix Inc. (1995–2025)
The table below shows the annual cash flow conversion efficiency of Soligenix Inc. from 1995 to 2025. Review SNGX FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.29 Million | $-10.27 Million | -1.940x | +4.93% |
| 2024-12-31 | $4.12 Million | $-8.40 Million | -2.041x | +40.17% |
| 2023-12-31 | $2.52 Million | $-8.60 Million | -3.411x | -166.63% |
| 2022-12-31 | $-2.47 Million | $-12.65 Million | 5.119x | +567.59% |
| 2021-12-31 | $10.72 Million | $-11.74 Million | -1.095x | +64.23% |
| 2020-12-31 | $3.74 Million | $-11.45 Million | -3.061x | +40.60% |
| 2019-12-31 | $1.46 Million | $-7.51 Million | -5.154x | -346.76% |
| 2018-12-31 | $6.28 Million | $-7.24 Million | -1.154x | -11.98% |
| 2017-12-31 | $6.32 Million | $-6.51 Million | -1.030x | -52.95% |
| 2016-12-31 | $7.40 Million | $-4.98 Million | -0.674x | -100.23% |
| 2015-12-31 | $-18.31K | $-5.39 Million | 294.189x | +1735.32% |
| 2014-12-31 | $-153.89K | $-2.47 Million | 16.029x | +536.51% |
| 2013-12-31 | $-1.77 Million | $-4.46 Million | 2.518x | +439.32% |
| 2012-12-31 | $3.55 Million | $-2.64 Million | -0.742x | -158.24% |
| 2011-12-31 | $6.79 Million | $-1.95 Million | -0.287x | +63.10% |
| 2010-12-31 | $7.36 Million | $-5.73 Million | -0.779x | -38.31% |
| 2009-12-31 | $8.17 Million | $-4.60 Million | -0.563x | +60.07% |
| 2008-12-31 | $1.98 Million | $-2.79 Million | -1.410x | +39.09% |
| 2007-12-31 | $2.59 Million | $-6.00 Million | -2.315x | -161.97% |
| 2006-12-31 | $-1.11 Million | $-4.14 Million | 3.737x | +222.25% |
| 2005-12-31 | $1.53 Million | $-4.67 Million | -3.057x | -106.90% |
| 2004-12-31 | $2.98 Million | $-4.41 Million | -1.477x | -83.67% |
| 2003-12-31 | $5.24 Million | $-4.22 Million | -0.804x | +42.56% |
| 2002-12-31 | $4.29 Million | $-6.00 Million | -1.400x | -192.57% |
| 2001-12-31 | $-2.63 Million | $-3.98 Million | 1.513x | +562.42% |
| 2000-12-31 | $10.55 Million | $-3.45 Million | -0.327x | -20.07% |
| 1999-12-31 | $7.26 Million | $-1.98 Million | -0.272x | +2.32% |
| 1998-12-31 | $14.70 Million | $-4.10 Million | -0.279x | -123.13% |
| 1997-12-31 | $18.40 Million | $-2.30 Million | -0.125x | +90.67% |
| 1996-12-31 | $1.12 Million | $-1.50 Million | -1.339x | -84.15% |
| 1995-12-31 | $1.38 Million | $-1.00 Million | -0.727x | -- |
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial fo… Read more